Azeloprazole - Eisai

Drug Profile

Azeloprazole - Eisai

Alternative Names: E-3710; Z 215

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; SFJ Pharmaceuticals; Zeria
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Erosive oesophagitis; Gastro-oesophageal reflux

Most Recent Events

  • 30 Jan 2018 Chemical structure information added
  • 01 Mar 2017 Zeria Pharmaceutical completes a phase II trial in Erosive oesophagitis in Japan (PO) (NCT02463643)
  • 18 Oct 2016 Phase-II clinical trials in Gastro-oesophageal reflux in USA (PO) (SFJ Pharmaceuticals pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top